The Clinical Investigations Support Office (CISO) serves as a centralized unit to oversee the clinical research infrastructure and assist investigators in their conduct of clinical trials and translational research projects. CISO has been reorganized following recommendations of an external advisory group and the Cancer Center Executive Committee and with the concurrence of the NCCC External Advisory Committee. The 58 personnel are now located in 15 of newly remodeled contiguous offices in the Ezralow Tower of the Cancer Center. CISO has three main operational units: 1) Protocol Administration;2) Protocol Implementation;and 3) Administrative/Business Management. The Protocol Administration Unit provides the centralized consultation and regulatory services necessary for the design, initiation, and conduct of externally-funded and internally peer-reviewed and monitored clinical trials. The Protocol Implementation Unit provides the centralized function of advising and assisting investigators in patient eligibility assessments, patient recruitment, data quality control and oversight. The Administrative/Business Management Unit was recently created in 2007 in order to coordinate CISO's relationships with institutional entities outside the Cancer Center and with sponsors. It is also charged with assisting the various investigators and sections to manage their funding sources, allocate their financial and human resources in an efficient manner, and be able to make sound projections for future growth. In addition to the services provided by the three operational units, CISO plays a central coordinating role within the Cancer Center through its interactions with other cores such as the Biostatistics Core, the Cancer Research Informatics Core (CRIC), the Translational Pathology Core, and the Protocol Review and Monitoring System entities (Clinical Investigations Committee and the Quality Assurance and Monitoring Committee). The Cancer Center Executive Committee exercises full authority over CISO policies and resource allocation and reviews the CISO's performance on a biannual basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-39
Application #
8589359
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$392,416
Indirect Cost
$142,794
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Lawrenson, Kate; Grun, Barbara; Lee, Nathan et al. (2015) NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer 136:1390-401
Milam, Joel E; Meeske, Kathleen; Slaughter, Rhona I et al. (2015) Cancer-related follow-up care among Hispanic and non-Hispanic childhood cancer survivors: The Project Forward study. Cancer 121:605-13
Maus, M K H; Hanna, D L; Stephens, C L et al. (2015) Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 15:354-62
Hirsch, Louis; Nazari, Hossein; Sreekumar, Parameswaran G et al. (2015) TGF-?2 secretion from RPE decreases with polarization and becomes apically oriented. Cytokine 71:394-6
Chuh, Kelly N; Pratt, Matthew R (2015) Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr Opin Chem Biol 24:27-37
Zhang, Hongjun; Boddupally, Keerthi; Kandyba, Eve et al. (2014) Defining the localization and molecular characteristic of minor salivary gland label-retaining cells. Stem Cells 32:2267-77
Wu, Dai-Ying; Ou, Chen-Yin; Chodankar, Rajas et al. (2014) Distinct, genome-wide, gene-specific selectivity patterns of four glucocorticoid receptor coregulators. Nucl Recept Signal 12:e002
Su, Sheng-Fang; de Castro Abreu, André Luís; Chihara, Yoshitomo et al. (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978-89
Tai, Kenneth P; Le, Valerie V; Selsted, Michael E et al. (2014) Hydrophobic determinants of ?-defensin bactericidal activity. Infect Immun 82:2195-202
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18

Showing the most recent 10 out of 345 publications